Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Luis Paz‐Ares(Hospital Universitario 12 De Octubre), C. Chouaïd(Université de Montpellier), Filippo de Marinis(Carlo Forlanini Hospital), Andreas Pircher(Innsbruck Medical University), Óscar Juan(Hospital Universitari i Politècnic La Fe), Stephen Della‐Fiorentina(Camden and Campbelltown Hospitals), Craig Underhill(AstraZeneca (United Kingdom)), Maximilian J. Hochmair(Karl Landsteiner Society), Riddhi Patel(Maharaja Sayajirao University of Baroda), Jaafar Bennouna(Hôpital Foch), Douglas Reznick(Rocky Mountain Cancer Centers), Jeremy Long, Kenneth J. O’Byrne(Translational Research Institute), Venessa Chin(Garvan Institute of Medical Research), Richard Greil(Paracelsus Medical University), Kevin Jasas, Elizabeth Ahern(Monash Health), Rami Nassabein(Centre Hospitalier de l’Université de Montréal), Paul Germonpré, Giannis Mountzios(Henry Dunant Hospital), Thierry Pieters, Alan A. Azambuja, Divyadeep Karumanchi(Gilead Sciences (United States)), Firas Badin, Parneet Cheema(University of Toronto), Robert H. El-Maraghi, İrfan Çiçin(Istinye University), Christos S. Karapetis(Clínica Alemana), Fábio Franke(National Cancer Center), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Scott Owen(McGill University Health Centre), Takayuki Takahama(Kindai University), Wim Demey(Inserm), Elke Govaerts, Sabeen Mekan(Gilead Sciences (United States)), Reinier Wener, Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Swati Kulkarni(Northwestern University), Enriqueta Felip(Institut Català d'Ornitologia), Nicolas Girard(Institut Curie), Marina Chiara Garassino(University of Chicago), Eduardo Silva(Hospitais da Universidade de Coimbra), Éric Zhang(Gilead Sciences (United States)), Suellen Castro, Felipe Melo Cruz(Instituto Brasileiro de Controle do Câncer), Giuliano Santos Borges, Clarisse Audigier-Valette(Hôpital d'Instruction des Armées Sainte-Anne), Louise Nott, Vipul M. Patel(Florida Cancer Specialists & Research Institute)
Cited by 126
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k